Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Theravance Biopharma, Inc.
TBPHNASDAQHealthcareBiotechnology
$17.03Today:- (-)1Y +21.30%
As of Sep 25, 2026 close
- Market cap
- $879.89M
- P/E (TTM)
- 16.35
- Forward P/E
- 8.23
- Dividend yield
- -
- 52-week range
- $13.08$21.03
- Volume (live)
- -
- Avg. volume (3M)
- 898.00K
Theravance Biopharma (TBPH) Key Statistics & Financial Metrics
Complete stock analysis with 60+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Book (mrq)3.04
Price/Tangible Book (mrq)3.04
Price/FCF (ttm)16.39
Price/OCF (ttm)16.37
PEG Ratio0.09
Enterprise Value Ratios
EV-based valuation multiples
Stock Price
Current price, 52-week range, and moving averages
Current Price$17.03
1-Day Change0.00%
52-Week High$21.03
52-Week Low$13.08
YTD Change−6.17%
1-Year Change+21.30%
50-Day MA$16.97
200-Day MA$17.17
Avg Volume (30 day)898.00K
Share Statistics
Outstanding shares, float, and per-share metrics
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Analyst ConsensusSell
Analyst Count1
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin86.03%
EBITDA Margin (ttm)60.25%
EBIT Margin (ttm)8.56%
Pretax Margin (ttm)56.48%
Profit Margin (ttm)51.58%
FCF Margin (ttm)51.48%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue104.31M
Gross Profit89.74M
Operating Income7.10M
Pretax Income58.92M
Net Income53.81M
EBITDA62.85M
EBIT8.93M
Diluted EPS$1.04
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Efficiency Metrics
Asset Turnover0.22
Growth Rates (YoY)
Year-over-year growth metrics
Revenue Growth+35.11%
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)469.77M
Cash & Securities (mrq)219.77M
Net Cash (mrq)+191.99M
Net Cash per Share+$3.72
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)27.77M
Working Capital (mrq)+385.90M
Total Equity (mrq)289.70M
Book Value per Share$5.61
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Financial Health Scores
Risk assessment and quality metrics
Fair Value & Intrinsic Value
Lynch fair value, Graham number, and valuation models
Lynch Fair Value$188.06
Lynch Upside/Downside+1004.29%
Graham Number$11.43
Graham Upside/Downside−32.89%
Source: Market prices and company fundamentals from financial filings. Data as of Sep 25, 2026. Data sources and methodology
Frequently Asked Questions About Theravance Biopharma Statistics
What are the key financial metrics for TBPH?
Theravance Biopharma, Inc. (TBPH) statistics include 60+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is TBPH's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Theravance Biopharma is overvalued or undervalued.
How do I read TBPH's profitability ratios?
Theravance Biopharma's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do TBPH's debt ratios indicate?
The financial health section shows Theravance Biopharma's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is TBPH's dividend analysis?
The dividend section covers Theravance Biopharma's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.